



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Suboxone

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
PSUSA/2113/202309	Periodic Safety Update EU Single assessment - buprenorphine / naloxone	30/05/2024	24/07/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/2113/202309.
WS/2621/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No	01/02/2024	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF				
IA/0058/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	30/10/2023	n/a		
N/0057	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/10/2023	05/01/2024	PL	
WS/2372/G	This was an application for a group of variations following a worksharing procedure according to	20/04/2023	n/a		

	Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.1.z - Change in immediate packaging of the finished product - Other variation				
IB/0055	C.z - Safety, Efficacy, Pharmacovigilance changes - Other variation	16/01/2023	05/01/2024	SmPC and Labelling	
WS/2324/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	10/11/2022	n/a		

	B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
IA/0054/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites	14/09/2022	n/a		

	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IB/0052	C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	30/08/2021	18/07/2022	SmPC, Annex II and PL	
WS/1993/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor	11/03/2021	n/a		

changes to an approved test procedure

B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure

B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure

B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS

B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of

a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised

	procedure is already authorised B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF				
IA/0051	A.7 - Administrative change - Deletion of manufacturing sites	08/02/2021	18/08/2021	SmPC, Labelling and PL	
IB/0049	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	29/01/2021	n/a		
IAIN/0048/G	This was an application for a group of variations.	11/12/2020	18/08/2021	SmPC, Annex	

	A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing			II, Labelling and PL	
IB/0047/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.z - Change in container closure system of the Finished Product - Other variation B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	17/11/2020	n/a		
IB/0046/G	This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	26/08/2020	18/08/2021	SmPC, Labelling and PL	

X/0042	Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration	30/04/2020	03/07/2020	SmPC, Labelling and PL	
PSUSA/2113/201909	Periodic Safety Update EU Single assessment - buprenorphine / naloxone	14/05/2020	n/a		PRAC Recommendation - maintenance
IAIN/0043/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release	27/03/2019	n/a		

	arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing				
WS/1489/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	21/03/2019	n/a		

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IA/0041	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	15/03/2019	n/a		
IAIN/0040/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	13/02/2019	04/02/2020	Annex II and PL	
T/0038	Transfer of Marketing Authorisation	09/05/2018	31/05/2018	SmPC, Labelling and PL	
II/0037	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission	17/05/2018	n/a		Analyses from the THIN study showed that the mortality rate appeared lower in the Suboxone user group than in

	of studies to the competent authority				the buprenorphine and methadone user groups. Two comparative analyses were conducted using the cohort design with intention-to-treat approach and the nested case control design. Both analyses yielded consistent results that Suboxone was not found associated with any elevated risk for all-cause mortality in comparison to buprenorphine or methadone. Based on the current findings, no safety signal was detected for Suboxone. Therefore, no change to the product information is warranted.
PSUSA/2113/201609	Periodic Safety Update EU Single assessment - buprenorphine / naloxone	05/05/2017	n/a		PRAC Recommendation - maintenance
WS/0934/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	23/03/2017	n/a		

	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised				
II/0035	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	09/03/2017	n/a		
X/0029	Annex I_2.(c) Change or addition of a new strength/potency	24/09/2015	16/11/2015	SmPC, Annex II, Labelling and PL	Please refer to the scientific discussion Suboxone-H-C-000697-X-0029-AR
IAIN/0033	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	25/08/2015	n/a		
IAIN/0032/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name	12/08/2015	16/11/2015	SmPC, Labelling and PL	

	and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings				
II/0030/G	This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	26/02/2015	30/03/2015	SmPC and PL	
IA/0031/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	07/01/2015	n/a		
IB/0027	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	12/08/2014	n/a		

IAIN/0025	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	21/05/2014	n/a		
PSUV/0023	Periodic Safety Update	08/05/2014	n/a		PRAC Recommendation - maintenance
IA/0024	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	10/04/2014	n/a		
II/0022	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	20/03/2014	n/a		
II/0021	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	20/03/2014	n/a		
II/0020	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	20/03/2014	n/a		
IAIN/0019/G	This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change	13/12/2013	n/a		

	to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State				
IAIN/0018	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	07/11/2013	n/a		
IA/0017	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	03/09/2013	23/05/2014	SmPC and PL	
IB/0015/G	This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised	11/07/2013	n/a		
IA/0016/G	This was an application for a group of variations. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement	03/07/2013	n/a		

	or addition of a site where batch control/testing takes place A.7 - Administrative change - Deletion of manufacturing sites B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions				
IA/0014/G	This was an application for a group of variations. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	24/06/2013	n/a		The Agency considers that the variation listed below is rejected and therefore receives an unfavourable opinion. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms
II/0013/G	This was an application for a group of variations. Changes to the Active Substance Master File (ASMF) for Buprenorphine Hydrochloride. B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement	30/05/2013	30/05/2013		

or addition) for the AS or a starting material/intermediate

B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF

B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits

B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure

B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method

B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method

B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits

B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method

B.I.b.1.c - Change in the specification parameters

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method				
II/0012/G	This was an application for a group of variations. Group of 8 type II variations: - Update to section 4.2 of the SmPC to add a clarification on withdrawal signs based on the literature. - Update to sections 4.4 and 4.6 of the SmPC to add new or revised warning, respectively, on the risk of respiratory depression in non-opioid dependent individuals, children and pregnant women, supported by relevant pharmacovigilance data. - Update to sections 4.4 and 4.8 of the SmPC, to strengthen existing warning on hepatic injury, supported by relevant pharmacovigilance data. - Update to sections 4.4 of the SmPC to strengthen the warning related to the use of suboxone in patient with severe renal impairment, supported by literature reference. - Update to sections 4.4 of the SmPC to strengthen general warning relevant to the administration of opioids, supported by literature references. - Update to section 4.5 of the SmPC to add information on the interaction of suboxone with full opioid agonist supported by literature references. - Update to sections 4.5 and 4.9 of the SmPC	30/05/2013		SmPC, Labelling and PL	The group of nine (9) type II variations was submitted as result from a pharmacovigilance audit conducted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 29-31 May and 19-20 July 2012, where it was identified that the EU Summary of Product Characteristics (SmPC) for Suboxone should be aligned with the current CCDS. The variations included proposed changes to the SmPC and the package leaflet, and the MAH took this opportunity to bring the PI in line with the QRD template version 9. Eight (8) of the variations were acceptable and the sections 4.2, 4.4, 4.5, 4.8, 4.9 of the SmPC were updated, and in particular: - a clarification was added on withdrawal signs based on the available literature data. - a new or revised warning, respectively, on the risk of respiratory depression in non-opioid dependent individuals, children and pregnant women, supported by relevant pharmacovigilance data was added. - strengthening of the existing warning on hepatic injury, supported by relevant pharmacovigilance data, was done. - the warning related to the use of suboxone in patient with severe renal impairment was strengthened. This is supported by literature reference. - The general warning relevant to the administration of opioids was strengthened, supported by literature

to add information on the interaction of suboxone with Naltrexone, supported by relevant literature references.

- Update to section 4.5 of the SmPC to add information on the interaction of suboxone and CYP3A4 inducers, supported by literature references. The PL was updated accordingly.

The MAH took the opportunity to make minor editorial changes to the SmPC.

Furthermore, the MAH proposed this opportunity to bring the PI in line with the QRD template version 9. The requested group of variations proposed amendments to the SmPC, Annex II, Labelling and Package Leaflet.

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the

references.

- Additional information on the interaction of suboxone with full opioid agonist supported by literature references was introduced.
- An update to the information on the interaction of suboxone with Naltrexone and CYP3A4 inducers was made, supported by relevant literature references.

In addition, the CHMP considers the following variation not acceptable:

- Update to section 4.8 of the SmPC, to reclassify 'injury' and 'heat stroke' under the MedDRA SOC 'drug withdrawal symptom', to add adverse events observed in post-marketing settings in accordance with current pharmacovigilance data.

MAH

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH

C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH

C.I.3.b - Implementation of change(s) requested

	following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH				
N/0011	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/09/2012	23/05/2014	PL	Update of the Package Leaflet (PL) to introduce changes related to the readability testing reports.
R/0008	Renewal of the marketing authorisation.	21/07/2011	16/09/2011	SmPC, Annex II, Labelling and PL	Reviewing the efficacy and safety data available for Suboxone since the granting of the marketing authorisation revealed no new major safety concerns. From the clinical perspective the CHMP considered that the overall benefit-risk ratio of Suboxone remained unchanged and was positive. The CHMP was of the opinion that the renewal could be granted with unlimited validity.
IB/0009/G	This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	02/08/2011	n/a		
T/0006	Transfer of Marketing Authorisation	06/07/2010	06/08/2010	SmPC, Labelling and PL	The Marketing Authorisation has been transferred from SP Europe to RB Pharmaceuticals Ltd.

N/0005	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	23/02/2009	n/a	PL	
N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/01/2008	n/a	PL	
II/0003	Update of the Package Leaflet Update of Package Leaflet	21/06/2007	30/07/2007	PL	The Package Leaflet has been updated to reflect the comments received following the User Readability Testing Assessment. More specifically a subheading titled "Misuse and abuse" was introduced in the Section 2 of the PL for clarification.
N/0002	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	24/04/2007	n/a	PL	
N/0001	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/12/2006	n/a	Labelling and PL	